Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Heart assist systems--current status].

Roland Hetzer1, Michael J Jurmann, Evgenij V Potapov

  • 1Abteilung für Herz-, Thorax- und Gefässchirurgie, Deutsches Herzzentrum Berlin. hetzer@dhzb.de

Herz
|October 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the contribution of rare variants to congenital heart disease through a large-scale case-control exome study.

NPJ genomic medicine·2026
Same author

Detecting early structural and functional myocardial alterations in patients with repaired tetralogy of fallot: a prospective MRI study.

Scientific reports·2026
Same author

Percutaneous Intervention in External Outflow Graft Obstruction of Magnetically Levitated Left Ventricular Assist Device: Long-Term Follow-Up and Quality of Life.

Artificial organs·2026
Same author

"Knowing is Not Enough; We Must Apply. Willing is Not Enough; We Must Do."

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Skin grafting while preconditioning with microaxial flow pump: case report of a successful bridge to candidacy approach.

European heart journal. Case reports·2026
Same author

Diagnosis and treatment strategies for cardiogenic shock in Takotsubo syndrome with a temporary left ventricular assist device-A single-center study.

JHLT open·2026

Artificial blood pumps offer a vital alternative for end-stage heart failure when transplantation isn't feasible. Advancements in left ventricular assist devices (LVADs) provide improved options for circulatory support and improved patient outcomes.

Area of Science:

  • Cardiac Surgery
  • Biomedical Engineering
  • Cardiology

Background:

  • Heart failure is a leading cause of death globally, necessitating advanced treatment options.
  • While heart transplantation offers good long-term results, its availability is limited.
  • Artificial blood pumps, particularly left ventricular assist devices (LVADs), are crucial for managing end-stage heart failure.

Purpose of the Study:

  • To review the current status and indications for artificial blood pumps in managing heart failure.
  • To compare different types of artificial blood pumps, including LVADs.
  • To assess the potential of artificial blood pumps for long-term circulatory support.

Main Methods:

  • Review of current literature on artificial blood pumps and their clinical applications.

Related Experiment Videos

  • Comparison of partially-implantable and fully-implantable LVADs.
  • Analysis of indications for paracorporeal and implantable blood pump systems.
  • Main Results:

    • Partially-implantable LVADs, especially axial-flow devices, offer advantages in size, energy, and implantation.
    • Fully-implantable devices are emerging but are more complex and have limited clinical data.
    • Artificial blood pumps are well-established for bridge-to-transplant and acute cardiac failure, with promising results in pediatric cases.

    Conclusions:

    • Artificial blood pumps are essential for patients with end-stage heart failure, offering alternatives to transplantation.
    • Advancements in LVAD technology are improving the feasibility of long-term circulatory support.
    • The increasing reliability and incidence of heart failure justify the long-term application of artificial blood pumps, particularly in older populations.